Coronary/Structural Heart

Children’s Minnesota and Mayo Clinic announce pediatric cardiovascular collaboration

Now one of the largest and strongest pediatric cardiovascular programs in the country MINNEAPOLIS, Aug. 18, 2020 /PRNewswire/ — Children’s Minnesota and Mayo Clinic announced today that they have reached the next phase of an agreement to collaborate in the care of children with congenital heart disease. This phase of the agreement adds pediatric […]

First AngelMed Guardian® Implants in Asia Pacific

EATONTOWN, N.J., Aug. 18, 2020 /PRNewswire/ — Key Highlights: First AngelMed Guardian® patient implants in Asia Pacific for Hydrix Medical, a subsidiary of Hydrix Limited (ASX: HYD) Four implants were carried out under the guidance of leading Cardiologist Dr. Leslie Lam This significant milestone provides a foundation for future implants under early access schemes in Singapore and Australia Angel […]

Virginia Cardiovascular Specialists Deploys PatientKeeper to Enable Providers to Access Patient Records and Capture Charges on Mobile Devices

EHR optimization software streamlines workflow for physicians practicing at Richmond-area HCA Virginia and Bon Secours hospitals WALTHAM, Mass., and RICHMOND, Va., Aug. 18, 2020 /PRNewswire/ — Virginia Cardiovascular Specialists (VCS), a leading cardiology practice in Richmond, VA, has deployed PatientKeeper® to enable its providers to have immediate access to patient records and to enter professional charges, anytime, […]

Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020

Data presentation will highlight efficacy, safety and tolerability of investigational medicine in patients with hypertriglyceridemia and cardiovascular disease BOSTON and CARLSBAD, Calif., Aug. 18, 2020 /PRNewswire/ — Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the Phase 2 study of AKCEA-APOCIII-LRx will be […]

Cytokinetics Announces Partnership to Improve Prediction of Risk and Outcomes in Hypertrophic Cardiomyopathy

Company Makes Long-term Commitment to Outcomes Research in HCM SOUTH SAN FRANCISCO, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq:CYTK) today announced a $1 million grant and four-year partnership with the HCM Registry (HCMR), a global registry of patients with hypertrophic cardiomyopathy (HCM) focused on improving predictive measures […]

New Pilot Study Indicates Niagen® May Reduce Inflammatory Cytokines in Stage D Heart Failure Patients

Niagen® (patented nicotinamide riboside) may reduce production of inflammatory cytokines in pilot study of Stage D heart failure patients LOS ANGELES–(BUSINESS WIRE)–ChromaDex Corp. (NASDAQ:CDXC) today announced the 11th published human trial on its patented NAD-boosting nutrient Niagen®, further highlighting its potential to support cardiovascular health in humans. A NIH funded study […]

Foldax Named a Finalist in the Fierce Innovation Awards – Life Sciences Edition 2020

Tria Heart Valve Made with Proprietary LifePolymer Reimagines Material, Design and Manufacturing to Solve Long-Standing Heart Valve Issues SALT LAKE CITY–(BUSINESS WIRE)–Foldax® announced today that it has been selected as a finalist in the Fierce Innovation Awards – Life Sciences Edition 2020, a peer-reviewed awards program from the publisher of Fierce Biotech and Fierce Pharma, […]

Philips introduces OmniWire, the world’s first solid core pressure guide wire for coronary artery interventional procedures

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the introduction of OmniWire, the world’s first solid core pressure wire for coronary artery interventional procedures. With its breakthrough solid core construction, physicians can more easily maneuver the wire in the patient’s circulatory system to […]

Neovasc Provides Corporate Update

VANCOUVER and MINNEAPOLIS, MN, Aug. 13, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE  — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today provided a corporate update on progress towards its value creation strategies. Fred Colen, Chief Executive Officer of Neovasc, commented, “We are pleased to provide a corporate update to our investors as we have […]